NewAmsterdam Pharma (NAMS) Net Income towards Common Stockholders (2023 - 2026)

NewAmsterdam Pharma has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$48.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$48.4 million, down 22.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$212.7 million (down 351.41% YoY), and the FY2025 annual result was -$203.8 million, down 101.07% from the prior year.
• Net Income towards Common Stockholders came in at -$48.4 million for Q1 2026 at NewAmsterdam Pharma, up from -$74.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $48.1 million in Q4 2024 to a low of -$93.8 million in Q1 2024.
• The 4-year median for Net Income towards Common Stockholders is -$44.6 million (2023), against an average of -$41.0 million.
• Across the five-year window, Net Income towards Common Stockholders surged 197.14% in 2024 and tumbled 332.54% in 2025, its largest moves.
• NewAmsterdam Pharma's Net Income towards Common Stockholders stood at -$49.5 million in 2023, then soared by 197.14% to $48.1 million in 2024, then sank by 255.91% to -$74.9 million in 2025, then soared by 35.35% to -$48.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$48.4 million (Q1 2026), -$74.9 million (Q4 2025), and -$72.0 million (Q3 2025), per Business Quant data.